Literature DB >> 31385276

Mutagenesis of Chlamydia trachomatis Using TargeTron.

Mary M Weber1, Robert Faris2.   

Abstract

Chlamydia trachomatis is an important human pathogen that prior to 2011 was largely intractable to genetic manipulation. Here we describe the application of a group II intron, referred to as TargeTron, for site-specific insertional inactivation of target genetic loci in the obligate, intracellular bacteria C. trachomatis. In this chapter, we outline the methods for intron retargeting, chlamydia transformation, and mutant verification. We also outline a method for complementation of TargeTron mutants. Furthermore, we discuss potential pitfalls and alternative strategies for generating mutants with TargeTron technology.

Entities:  

Keywords:  Chlamydia trachomatis; Complementation; Group II intron; Insertional inactivation; TargeTron

Mesh:

Substances:

Year:  2019        PMID: 31385276     DOI: 10.1007/978-1-4939-9694-0_12

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  2 in total

1.  The Chlamydia trachomatis secreted effector TmeA hijacks the N-WASP-ARP2/3 actin remodeling axis to facilitate cellular invasion.

Authors:  Robert Faris; Alix McCullough; Shelby E Andersen; Thomas O Moninger; Mary M Weber
Journal:  PLoS Pathog       Date:  2020-09-18       Impact factor: 6.823

2.  A broad-spectrum cloning vector that exists as both an integrated element and a free plasmid in Chlamydia trachomatis.

Authors:  Lotisha Garvin; Rebecca Vande Voorde; Mary Dickinson; Steven Carrell; Kevin Hybiske; Daniel Rockey
Journal:  PLoS One       Date:  2021-12-16       Impact factor: 3.752

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.